Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of PMN-310 for Alzheimer's Disease

Trial Profile

A Phase 1 Study of PMN-310 for Alzheimer's Disease

Planning
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2018

At a glance

  • Drugs PMN 310 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Nov 2018 According to a ProMIS Neurosciences media release, this trial will use an innovative clinical trial design using emerging biomarkers that may indicate early signs of efficacy.The company expects to generate initial clinical results by end of 2020.
    • 12 Jun 2018 According to a ProMIS Neurosciences media release, the molecule PMN310 is anticipated to enter phase 1 trial in second half of 2019.
    • 13 Sep 2017 According to a ProMIS Neurosciences media release, the molecule PMN310 is on track for initiation of this trial in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top